{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:04:58Z","timestamp":1777640698831,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012282","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000}}],"reference-count":334,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012282.pub2","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T04:12:39Z","timestamp":1520309559000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Fluvastatin for lowering lipids"],"prefix":"10.1002","volume":"2018","author":[{"given":"Stephen P","family":"Adams","sequence":"first","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall, Medical Block C Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarpreet S","family":"Sekhon","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall, Medical Block C Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tsang","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Internal Medicine, Internal Medicine Residency Office, Faculty of Medicine; 1200 Main Street West HSC 3W10 Hamilton ON Canada L8N 3N5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Wright","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall, Medical Block C Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0001|cit1","first-page":"272","article-title":"Antihypertensive effect of a cholesterol-lowering agent (fluvastatin). Pilot study","volume":"128","author":"Abetel","year":"1998","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(01)00799-9","article-title":"Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins","volume":"111","author":"Andrews","year":"2001","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0002-9149(01)01638-1","article-title":"Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels","volume":"88","author":"Ballantyne","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012282.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321001-00002","article-title":"An Economic Analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)","volume":"21","author":"Smith","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.linthera.2008.01.013","article-title":"Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study","volume":"30","author":"AlvarezSala","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0006|cit6","unstructured":"Novartis A multicenter, randomized, open-label, parallel-group study to evaluate the efficacy and safety of the combination of extended-release fluvastatin with ezetimibe versus extended-release fluvastatin alone on low density lipoprotein ( LDL) cholesterol levels Study Number CXUO320BES03 2005"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0007|cit7","unstructured":"Novartis Efficacy and safety study of fluvastatin and ezetimibe combined versus fluvastatin alone ClinicalTrials.gov 2011"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012282.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003495-199400472-00011","article-title":"Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolemic women","volume":"47","author":"Baggio","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0011-393X(05)80525-9","article-title":"Efficacy and safety of fluvastatin in elderly hypercholesterolemic patients: A pilot study","volume":"55","author":"Baggio","year":"1994","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/0026-0495(95)90145-0","article-title":"Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition","volume":"44","author":"Bard","year":"1995","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/107424849600100203","article-title":"A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia","volume":"1","author":"Berger","year":"1996","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"6 PART A","key":"10.1002\/14651858.CD012282.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1016\/0002-9343(94)90232-1","article-title":"Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia","volume":"96","author":"Betteridge","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0002-9149(96)00684-4","article-title":"Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease","volume":"79","author":"Bevilacqua","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.curtheres.2004.06.004","article-title":"Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: A 4-month, prospective, open-label, randomized, blinded-end point (Probe) trial","volume":"65","author":"Bevilacqua","year":"2004","journal-title":"Current Therapeutic Research - Clinical & Experimental"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF02849947","article-title":"Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes","volume":"22","author":"Bevilacqua","year":"2005","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s001980170106","article-title":"The effect of fluvastatin on parameters of bone remodeling","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s002280050663","article-title":"Lowering effects of four different statins on serum triglyceride level","volume":"55","author":"Branchi","year":"1999","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"128","key":"10.1002\/14651858.CD012282.pub2-BIB0018|cit18","first-page":"107","article-title":"[Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia]","volume":"22","author":"Broncel","year":"2007","journal-title":"Polski Merkuriusz Lekarski"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0735-1097(98)00300-3","article-title":"Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin","volume":"32","author":"Brown","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1076-7460.2003.02000.x","article-title":"Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients","volume":"12","author":"Bruckert","year":"2003","journal-title":"American Journal of Geriatric Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2217\/14622416.9.9.1217","article-title":"Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy","volume":"9","author":"Couvert","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s102380300015","article-title":"Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects","volume":"3","author":"Bruni","year":"2003","journal-title":"Clinical and Experimental Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"CR512","DOI":"10.12659\/MSM.883272","article-title":"Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population","volume":"18","author":"Buzkova","year":"2012","journal-title":"Medical Science Monitor : International Medical Journal of Experimental and Clinical Research"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0011-393X(97)80068-9","article-title":"Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia","volume":"58","author":"Buzzi","year":"1997","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0025|cit25","first-page":"533","article-title":"Fluvastatin in the treatment of hyperlipoproteinemia, preliminary results","volume":"42","author":"Ceska","year":"1996","journal-title":"Vnitrni Lekarstvi"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/147323000203000104","article-title":"Effects of fluvastatin treatment on insulin sensitivity in patients with hyperlipidaemia","volume":"30","author":"Cingozbay","year":"2002","journal-title":"Journal of International Medical Research"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1592\/phco.20.9.819.35197","article-title":"Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: analysis based on the CURVES study","volume":"20","author":"Hilleman","year":"2000","journal-title":"Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0028|cit28","first-page":"1573","article-title":"The curves trial: A pharmacoeconomic evaluation","volume":"3","author":"Hilleman","year":"1997","journal-title":"American Journal of Managed Care"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0029|cit29","first-page":"1107","article-title":"The CURVES trial: A pharmacoeconomic evaluation","volume":"17","author":"Hilleman","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0032|cit30","first-page":"128","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study) (vol 81, pg 582, 1998)","volume":"82","author":"Jones","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0030|cit31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0031|cit32","first-page":"202","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"11","author":"Jones","year":"1998","journal-title":"Perfusion"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0034|cit33","first-page":"407","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study) - Reply","volume":"82","author":"Jones","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"ABSTR. SUPPL.","key":"10.1002\/14651858.CD012282.pub2-BIB0035|cit34","first-page":"371","article-title":"Comparison of the dose efficacy of atorvastatin with pravastatin, simvastatin, fluvastatin and lovastatin: The CURVES study","volume":"18","author":"Jones","year":"1997","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0033|cit35","unstructured":"Jones PH Blumenthal RS Comparative dose efficacy of statins Cardiology Review 1998 25 9"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0036|cit36","first-page":"S232","article-title":"The CURVES study - A comparison of the dose efficacy of atorvastatin with pravastatin, simvastatin, fluvastatin and lovastatin","volume":"16","author":"Kafonek","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0037|cit37","first-page":"406","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"82","author":"Pincus","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0038|cit38","first-page":"9","article-title":"Cost effectiveness of HMG-CoA reductase inhibition in Canada","volume":"8","author":"Russell","year":"2001","journal-title":"Canadian Journal of Clinical Pharmacology = Journal Canadien de Pharmacologie Clinique"},{"issue":"6 PART A","key":"10.1002\/14651858.CD012282.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1016\/0002-9343(94)90229-1","article-title":"Fluvastatin reduces levels of plasma Apo B-containing particles and increases those of LpA-I","volume":"96","author":"Dallongeville","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"6 PART A","key":"10.1002\/14651858.CD012282.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1016\/0002-9343(94)90229-1","article-title":"Fluvastatin reduces levels of plasma Apo B-containing particles and increases those of LpA-I","volume":"96","author":"Dallongeville","year":"1994","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0041|cit41","first-page":"95","article-title":"Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group","volume":"736","author":"Dallongeville","year":"1994","journal-title":"Journal of Internal Medicine. Supplement"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/S0149-2918(03)80330-2","article-title":"A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg\/d with fluvastatin 20 and 40 mg\/d","volume":"25","author":"Davidson","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.vph.2003.09.002","article-title":"Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype","volume":"40","author":"Dergunov","year":"2003","journal-title":"Vascular Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/BF02849954","article-title":"Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure","volume":"22","author":"Lullo","year":"2005","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0045|cit45","first-page":"138","article-title":"Efficacy and safety of fluvastatin in patients with non-insulin- dependent diabetes mellitus and hypercholesterolemia","volume":"13","author":"Ding","year":"1997","journal-title":"Acta Cardiologica Sinica"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/0002-9343(94)90230-5","article-title":"Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy","volume":"96","author":"Dujovne","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1755-5922.2010.00141.x","article-title":"STATIN-D Study: Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D","volume":"29","author":"Ertugrul","year":"2011","journal-title":"Cardiovascular Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"57A","DOI":"10.1016\/S0002-9149(05)80019-0","article-title":"Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibratefor hypercholesterolemia","volume":"76","author":"Fanghanel","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0049|cit49","first-page":"151","article-title":"The efficacy, safety and tolerance of fluvastatin sodium 40 mg in patients with hyperlipidemia type IIA","volume":"66","author":"Fanghanel Salmon","year":"1996","journal-title":"Archivos del Instituto de Cardiologia de Mexico"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00044011-200121020-00003","article-title":"Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women","volume":"21","author":"Fernandez","year":"2001","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0051|cit51","first-page":"43","article-title":"[The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters]","volume":"69","author":"Filippova","year":"1997","journal-title":"Terapevticheskii Arkhiv"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0052|cit52","first-page":"1679","article-title":"[Clincal efficacy of fluvastatin (XU62-320) in hyperlipidemia: A comparative study with pravastatin in a double-blind Comparative method]","volume":"11","author":"Fluvastatin Study Group in Japan","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1419-21, A10","DOI":"10.1016\/j.amjcard.2004.02.046","article-title":"Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia","volume":"93","author":"Fujimoto","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"3-4","key":"10.1002\/14651858.CD012282.pub2-BIB0054|cit54","first-page":"285","article-title":"Saudi Arabia experience trial of fluvastatin (Lescol) in the treatment of hyperlipidemia","volume":"72","author":"Galal","year":"1997","journal-title":"Journal of the Egyptian Public Health Association"},{"issue":"23","key":"10.1002\/14651858.CD012282.pub2-BIB0055|cit55","first-page":"2528","article-title":"[Effective observation of Xue Zhi Kang and Fluvastatin for adjusting blood fat of coronary patient]","volume":"12","author":"Gao","year":"2003","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine [Xian Dai Zhong Xi Yi Jie He za Zhi]"},{"issue":"3-4","key":"10.1002\/14651858.CD012282.pub2-BIB0056|cit56","first-page":"110","article-title":"The effect of fluvastatin on hypercholesterolemia in patients with nephrotic syndrome","volume":"20","author":"Ghods","year":"1995","journal-title":"Iranian Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0057|cit57","unstructured":"Goedecke C Microscopic examination of the capillary microcirculation under the influence of the HMG-CoA reductase inhibitor fluvastatin in patients with hypercholesterolemia ProQuest Dissertations and Theses 2002"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5387\/fms.57.19","article-title":"Fluvastatin increases bone mineral density in postmenopausal women","volume":"57","author":"Gotoh","year":"2011","journal-title":"Fukushima Journal of Medical Science"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1016\/0002-9343(94)90233-X","article-title":"Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate","volume":"96","author":"Greten","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5551\/jat.11.56","article-title":"Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1","volume":"11","author":"Guan","year":"2004","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0021-9150(00)00567-0","article-title":"Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia","volume":"155","author":"Haak","year":"2001","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0062|cit62","first-page":"879","article-title":"Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia","volume":"46","author":"Hailer","year":"1996","journal-title":"Arzneimittel-Forschung"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0011-393X(03)00060-2","article-title":"Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: A twenty-four-week, open-label, dose-increasing study","volume":"64","author":"Homma","year":"2003","journal-title":"Current Therapeutic Research - Clinical & Experimental"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0049-3848(99)00037-7","article-title":"Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor","volume":"95","author":"Huhle","year":"1999","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0065|cit65","first-page":"349","article-title":"Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease","volume":"47","author":"Hunninghake","year":"1998","journal-title":"Journal of Family Practice"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0066|cit66","first-page":"469","article-title":"Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia","volume":"9","author":"Hunninghake","year":"2002","journal-title":"British Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00005344-200207000-00004","article-title":"Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients","volume":"40","author":"Hussein","year":"2002","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/ndt\/17.8.1513","article-title":"Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus","volume":"17","author":"Ichihara","year":"2002","journal-title":"Nephrology, Dialysis, Transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2710.2010.01161.x","article-title":"Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan","volume":"36","author":"Inoue","year":"2011","journal-title":"Journal of Clinical Pharmacy & Therapeutics"},{"issue":"21","key":"10.1002\/14651858.CD012282.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/archinte.1994.00420210087010","article-title":"Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia","volume":"154","author":"Insull","year":"1994","journal-title":"Archives of Internal Medicine"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012282.pub2-BIB0071|cit71","first-page":"50","article-title":"Comparative efficacy, safety , and tolerability of cerivastatin A new HMG-CoA reductase inhibitor, and fluvastatin in subjects with primary hypercholesterolemia","volume":"56","author":"Isaacsohn","year":"1999","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0149-2918(03)80113-3","article-title":"Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia","volume":"25","author":"Isaacsohn","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0073|cit73","first-page":"103","article-title":"[Clinical effect of fluvastatin (XU62-320) on hyperlipidemia: double-blind comparative preliminary dose-finding study in four parallel groups]","volume":"11","author":"Itakura","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0074|cit74","first-page":"45","article-title":"[The effects of the long-term treatment of fluvastatin, a newly developed HMG-CoA reductase inhibitor, on serum lipid and endocrine function in hyperlipidemic subjects]","volume":"11","author":"Ito","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"25D","DOI":"10.1016\/0002-9149(94)90629-7","article-title":"Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety","volume":"73","author":"Jacobson","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0002-9149(94)90088-4","article-title":"Fluvastatin with and without niacin for hypercholesterolemia","volume":"74","author":"Jacobson","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1016\/0002-9343(94)90234-8","article-title":"Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy","volume":"96","author":"Jacobson","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.1994.tb04350.x","article-title":"Efficacy of a low dose-range of fluvastatin (Xu-62-320) in the treatment of primary hypercholesterolemia - a dose-response study in 431 patients","volume":"38","author":"Jacotot","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"54A","DOI":"10.1016\/S0002-9149(05)80018-9","article-title":"Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia","volume":"76","author":"Jacotot","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"34","key":"10.1002\/14651858.CD012282.pub2-BIB0080|cit80","first-page":"1857","article-title":"[Effect of fluvastatin on serum lipid levels in essential hypertension]","volume":"137","author":"Jarai","year":"1996","journal-title":"Orvosi Hetilap"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0081|cit81","first-page":"103","article-title":"Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus","volume":"736","author":"Jokubaitis","year":"1994","journal-title":"Journal of Internal Medicine. Supplement"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1016\/0002-9343(94)90235-6","article-title":"Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia","volume":"96","author":"Knopp","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"39D","DOI":"10.1016\/0002-9149(94)90631-9","article-title":"Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report","volume":"73","author":"Knopp","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1358836X9900400405","article-title":"Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease","volume":"4","author":"Khan","year":"1999","journal-title":"Vascular Medicine (London, England)"},{"issue":"85","key":"10.1002\/14651858.CD012282.pub2-BIB0085|cit85","first-page":"42","article-title":"Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease","volume":"15","author":"Klosiewicz-Latoszek","year":"2003","journal-title":"Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0086|cit86","first-page":"34","article-title":"Achieving LDL goals: A comparison of four statins","volume":"16","author":"Koren","year":"1999","journal-title":"Cardiology Review"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.fjc.0000246150.52382.07","article-title":"Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention","volume":"48","author":"Kowalski","year":"2006","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0088|cit88","first-page":"4","article-title":"Assessment of efficacy of fluvastatin and fenofibrate in patients with noninsulin-dependent diabetes with hypercholesterolemia and combined hyperlipidemia","volume":"40","author":"Kozlov","year":"2000","journal-title":"Kardiologiya"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0089|cit89","unstructured":"Lan W Clinical features and risk of coronary heart disease in familial hypercholesterolaemia and studies on hypolipidaemic drug treatment in Hong Kong Chinese ProQuest Dissertations and Theses Global Ph.D. 2001"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0090|cit90","first-page":"I","article-title":"Effects of fluvastatin on atherosclerosis","volume":"14","author":"Aldrete","year":"1998","journal-title":"Medicina Interna de Mexico"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.99.6.736","article-title":"Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy","volume":"99","author":"Ballantyne","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0092|cit92","first-page":"12","article-title":"Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS)","volume":"19","author":"Ballantyne","year":"1998","journal-title":"Cardiovascular Reviews and Reports"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00008571-200401000-00007","article-title":"Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study","volume":"14","author":"Chen","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0100|cit94","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-94-011-5022-4_31","article-title":"Lessons from clinical trials: LCAS and other studies","volume-title":"Medical Science Symposia Series; Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronary Heart Disease, Cardiac Failure, and Stroke","volume":"12","author":"Herd","year":"1998"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0101|cit95","first-page":"36","article-title":"The effect of fluvastatin on coronary atherosclerosis: The Lipoprotein and Coronary Atherosclerosis Study (LCAS)","volume":"29","author":"Herd","year":"1997","journal-title":"Herz Kreislauf"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0102|cit96","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/S0002-9343(98)00187-9","article-title":"The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events","volume":"104","author":"Herd","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0094|cit97","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0002-9149(97)00346-9","article-title":"Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])","volume":"80","author":"Herd","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0095|cit98","first-page":"3496","article-title":"The effect of fluvastatin on coronary atherosclerosis: The lipoprotein and coronary atherosclerosis study (LCAS)","volume":"94","author":"Herd","year":"1996","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0097|cit99","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/0002-9149(94)90632-7","article-title":"Base-line characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (Lcas) with fluvastatin","volume":"73","author":"Herd","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0096|cit100","doi-asserted-by":"crossref","first-page":"42D","DOI":"10.1016\/0002-9149(94)90632-7","article-title":"Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin","volume":"73","author":"Herd","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"8 SUPPL.","key":"10.1002\/14651858.CD012282.pub2-BIB0098|cit101","first-page":"I27","article-title":"Predictors of clinical cardiac and all fatal events in the Lipoprotein and Coronary Atherosclerosis Study (LCAS)","volume":"96","author":"Herd","year":"1997","journal-title":"Circulation"},{"issue":"2 SUPPL. A","key":"10.1002\/14651858.CD012282.pub2-BIB0099|cit102","first-page":"139A","article-title":"Influence of age and sex on angiographic change in the lipoprotein and coronary atherosclerosis study (LCAS)","volume":"29","author":"Herd","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/hh0901.090301","article-title":"Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy","volume":"88","author":"Lutucuta","year":"2001","journal-title":"Circulation Research"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0735-1097(99)00535-5","article-title":"Interactions between angiotensin-I converting enzyme insertion\/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study","volume":"35","author":"Marian","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00109-002-0381-z","article-title":"Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin","volume":"80","author":"Salek","year":"2002","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-9150(99)00004-0","article-title":"Lipoprotein lipase gene mutations, plasma lipid levels, progression\/regression of coronary atherosclerosis, response to therapy, and future clinical events: Lipoproteins and Coronary Atherosclerosis Study","volume":"144","author":"Sing","year":"1999","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0021-9150(00)00495-0","article-title":"A prospective study of paraoxonase gene Q\/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin","volume":"154","author":"Turban","year":"2001","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0108|cit108","first-page":"76","article-title":"The Lipoprotein and Coronary Atherosclerosis Study (LCAS) confirms the benefit of lipid lowering for example with fluvastatin","volume":"2","author":"Vollmer","year":"1998","journal-title":"Therapie und Erfolg"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0197-2456(96)00178-X","article-title":"The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia","volume":"17","author":"West","year":"1996","journal-title":"Controlled ClinicalTtrials"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0197-2456(97)91228-9","article-title":"Erratum: The lipoprotein and coronary atherosclerosis study (LCAS): Design, methods and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia","volume":"18","author":"West","year":"1997","journal-title":"Controlled Clinical Trials"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD012282.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2165\/00003495-199400472-00010","article-title":"Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia","volume":"47","author":"Leitersdorf","year":"1994","journal-title":"Drugs"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00315307","article-title":"Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia","volume":"45","author":"Leitersdorf","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012282.pub2-BIB0113|cit113","first-page":"III35","article-title":"Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia","volume":"87","author":"Leitersdorf","year":"1993","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(94)90165-1","article-title":"Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination","volume":"96","author":"Leitersdorf","year":"1994","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/S0002-9149(05)80025-6","article-title":"Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia","volume":"76","author":"Leitersdorf","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002280050338","article-title":"Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals","volume":"53","author":"Leonhardt","year":"1997","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0117|cit117","first-page":"914","article-title":"Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia","volume":"103","author":"Leu","year":"2004","journal-title":"Journal of the Formosan Medical Association = Taiwan yi zhi"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/clc.4960280907","article-title":"Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia","volume":"28","author":"Leu","year":"2005","journal-title":"Clinical Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0119|cit119","first-page":"600","article-title":"The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia","volume":"16","author":"Lin","year":"2000","journal-title":"Kaohsiung Journal of Medical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"97A","DOI":"10.1016\/S0002-9149(05)80027-X","article-title":"Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency","volume":"76","author":"Lintott","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2004.03.067","article-title":"Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy","volume":"149","author":"Arampatzis","year":"2005","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0122|cit122","first-page":"331","article-title":"Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands \u00a0 \u00a0 associated included citation for the LIPS trial","volume":"12","author":"Chaplin","year":"2004","journal-title":"Netherlands Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1345\/aph.1E367","article-title":"Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention","volume":"39","author":"Delea","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0124|cit124","first-page":"1156","article-title":"Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)","volume":"90","author":"Lee","year":"2004","journal-title":"Heart (London)"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0126|cit125","first-page":"12","article-title":"Fluvastatin treatment after first PCI \u00a0","volume":"20","author":"Lemos","year":"2003","journal-title":"Cardiology Review"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0125|cit126","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2004.10.008","article-title":"Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy)","volume":"95","author":"Lemos","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijcard.2003.11.031","article-title":"Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease","volume":"98","author":"Lemos","year":"2005","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/S0149-2918(03)80285-0","article-title":"A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS","volume":"25","author":"Lesaffre","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3949\/ccjm.70.6.561","article-title":"The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI","volume":"70","author":"Messerli","year":"2003","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0130|cit130","unstructured":"Novartis Clinical Study Report SNDA #20-261 SE1 033 C and #21-192 SE1 005 C (LIPS) assessed: https:\/\/fda.opentrials.net\/search URL: file:\/\/\/C:\/Users\/Stephen%20Adams\/Documents\/LIPS%20Clinical%20Study%20Report%20from%20the%20FDA%20opentrials.pdf 2003"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2003.08.076","article-title":"Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation","volume":"93","author":"Saia","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/14737167.5.2.113","article-title":"Use of fluvastatin following percutaneous coronary intervention","volume":"5","author":"Scuffham","year":"2005","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.clinthera.2005.09.012","article-title":"A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention","volume":"27","author":"Scuffham","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00019053-200422080-00004","article-title":"An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK","volume":"22","author":"Scuffham","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10557-006-8877-3","article-title":"The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention","volume":"20","author":"Scuffham","year":"2006","journal-title":"Cardiovascular Drugs & Therapy"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Serruys PWJC De Feyter PJ Benghozi R Hugenholtz PG Lesaffre E The Lescol Intervention Prevention Study (LIPS): A double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease International Journal of Cardiovascular Interventions 2001 165 72","DOI":"10.1080\/14628840127765"},{"issue":"24","key":"10.1002\/14651858.CD012282.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0049-3848(97)00143-6","article-title":"Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction","volume":"87","author":"Lorena","year":"1997","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2010.12.041","article-title":"Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study","volume":"215","author":"Lunder","year":"2011","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejim.2011.11.011","article-title":"The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial","volume":"23","author":"Lunder","year":"2012","journal-title":"European Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00019501-199809090-00005","article-title":"Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin","volume":"9","author":"Lye","year":"1998","journal-title":"Coronary Artery Disease"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0142|cit142","first-page":"386","article-title":"The effect of fluvastatin on QT dispersion and lipid levels","volume":"55","author":"Mark","year":"2001","journal-title":"Kardiologia Polska"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0143|cit143","unstructured":"Martin NI [Untersuchungen zum Einfluss von Fluvastatin auf die Mikrozirkulation bei Patienten mit Hypercholesterinamie durchgefuhrt mittels Laser Doppler Technik] ProQuest Dissertations and Theses Dr. 2002"},{"issue":"15","key":"10.1002\/14651858.CD012282.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.CIR.103.15.1942","article-title":"Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype","volume":"103","author":"Marz","year":"2001","journal-title":"Circulation"},{"issue":"6-7","key":"10.1002\/14651858.CD012282.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0753-3322(96)84824-4","article-title":"Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia","volume":"50","author":"Milani","year":"1996","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"51A","DOI":"10.1016\/S0002-9149(05)80017-7","article-title":"Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia","volume":"76","author":"Milani","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2125.2008.03213.x","article-title":"The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters","volume":"66","author":"Mirdamadi","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0148|cit148","first-page":"97","article-title":"A comparison between fluvastatin and lovastatin effects in Iranian patients with hypercholesterolemia","volume":"36","author":"Moradmand","year":"1998","journal-title":"Acta Medica Iranica"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0149-2918(01)80050-3","article-title":"A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease","volume":"23","author":"Dam","year":"2001","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0150|cit150","first-page":"213","article-title":"[Clinical Effect of Fluvastatin (XU62-320) on Hyperlipidemia: Comparative Study with Placebo in a Double-Blind Method]","volume":"11","author":"Nakaya","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"6A","key":"10.1002\/14651858.CD012282.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0002-9149(96)00659-5","article-title":"Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention","volume":"78","author":"Nash","year":"1996","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0152|cit152","unstructured":"NOVARTIS A 16 week open label randomised prospective study on vasoprotective efficacy and safety if monotherapy fluvastatin extended release (XL) 80 mg or valsartan 160 mg and their combination in dyslipidemic patients with arterial hypertension and endothelial dysfunction Study Number CXUO320BRU01 2005"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0153|cit153","unstructured":"NOVARTIS A sixteen-week, double-blind, double-dummy, randomized, parallel-group, multicenter, active controlled study to assess the efficacy and safety of fluvastatin 80 mg slow release (SR) tablet compared to fluvastatin 40 mg immediate release capsule both once daily at bedtime in patients with mixed dyslipidemia or primary hypercholesterolemia Study Number CXUO320B2302 2006"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000175455.46245.c8","article-title":"Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates","volume":"46","author":"Okopien","year":"2005","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2004.05.009","article-title":"The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia","volume":"176","author":"Okopien","year":"2004","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0156|cit156","first-page":"781","article-title":"Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia","volume":"56","author":"Okopien","year":"2004","journal-title":"Polish Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0149-2918(01)80029-1","article-title":"Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial","volume":"23","author":"Olsson","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0021-9150(96)05972-2","article-title":"Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL","volume":"128","author":"Hussein","year":"1997","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2125.1997.00625.x","article-title":"Reduced platelet agregation after fluvastatin therapy is associated with altered platelelt lipid composition and drug binding to the platelets","volume":"44","author":"Osamah","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00044011-199510030-00001","article-title":"Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia","volume":"10","author":"Ose","year":"1995","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0161|cit161","doi-asserted-by":"crossref","unstructured":"Parks MH Study CXUO320BZA01 NDA 20-261 and 21-192 2006","DOI":"10.1016\/S0262-4079(06)61379-1"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0162|cit162","first-page":"45","article-title":"[The hypolipidemic effect of and tolerance for Lescol in treating hypercholesterolemia in hypertension patients (an analysis of the data from a multicenter study)]","volume":"67","author":"Aronov","year":"1995","journal-title":"Terapevticheskii Arkhiv"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0163|cit163","first-page":"23","article-title":"The association between the ability of fluvastatin (lescol) to correct atherogenic dyslipoproteinemias and human plasma lipoprotein spectra and drug dosage","volume":"5","author":"Perova","year":"1996","journal-title":"Clinical Pharmacology and Therapeutics (Russia)"},{"issue":"3-4","key":"10.1002\/14651858.CD012282.pub2-BIB0164|cit164","first-page":"193","article-title":"Plasma lipids and blood fluidity in patients with polygenic hypercholesterolaemia treated with fluvastatin","volume":"27","author":"Pinon","year":"2002","journal-title":"Clinical Hemorheology and Microcirculation"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s002280000254","article-title":"Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index","volume":"56","author":"Porsch-Ozcurumez","year":"2001","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0166|cit166","first-page":"378","article-title":"Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects","volume":"11","author":"Puccetti","year":"2001","journal-title":"Nutrition Metabolism & Cardiovascular Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2362.2002.01086.x","article-title":"Time-dependent effect of statins on platelet function in hypercholesterolaemia","volume":"32","author":"Puccetti","year":"2002","journal-title":"European Journal of Clinical Investigation"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(99)00062-3","article-title":"The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment","volume":"144","author":"Riegger","year":"1999","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1002\/14651858.CD012282.pub2-BIB0169|cit169","first-page":"13","article-title":"[Efficacy and safety of treating hyperlipidemia type II with fluvastatin in patients with arterial hypertension]","volume":"3","author":"Rywik","year":"1997","journal-title":"Polski Merkuriusz Lekarski"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0170|cit170","first-page":"153","article-title":"[Clinical effect of fluvastatin (XU62-320) on hyperlipidemia: double-blind comparative dose-finding study in three parallel groups]","volume":"11","author":"Saito","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005344-200003000-00005","article-title":"Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects","volume":"35","author":"Saitta","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0172|cit172","first-page":"30","article-title":"Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes","volume":"4","author":"Sarano","year":"2003","journal-title":"Kardiologiia"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0173|cit173","first-page":"279","article-title":"[Effects of fluvastatin (XU62-320), a new inhibitor of HMG-CoA reductase, combined with niceritrol in primary hypercholesterolemic patients]","volume":"11","author":"Sasaki","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0174|cit174","first-page":"420","article-title":"Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients","volume":"33","author":"Sasaki","year":"1995","journal-title":"International Journal of Clinical Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000093200","article-title":"Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration","volume":"106","author":"Scharnagl","year":"2006","journal-title":"Cardiology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0176|cit176","unstructured":"Levin LA Schmidt A Schulte K-L Beil S Fager G A comparison of clinical and pharmacoeconomic properties of fluvastatin and simvastatin in the management of primary hypercholesterolaemia British Journal of Medical Economics 1997 23 35"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00044011-199612030-00001","article-title":"Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients: A double-blind, randomised, parallel- group comparison","volume":"12","author":"Schulte","year":"1996","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0178|cit178","first-page":"414","article-title":"The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia","volume":"25","author":"Sejda","year":"2006","journal-title":"International Angiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.metabol.2005.03.021","article-title":"Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia","volume":"54","author":"Seres","year":"2005","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0180|cit180","first-page":"7","article-title":"Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia","volume":"53","author":"Sigurdsson","year":"1998","journal-title":"Acta Cardiologica"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0181|cit181","first-page":"298","article-title":"Fluvastatin and fish oil are more effective on cardiovascular risk factors than fluvastatin alone","volume":"53","author":"Singer","year":"2002","journal-title":"Medizinische Welt"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0026-0495(99)90239-1","article-title":"Combined hyperlipidemia is associated with increased exercise-induced muscle protein release which is improved by triglyceride-lowering intervention","volume":"48","author":"Smit","year":"1999","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"126A","DOI":"10.1016\/S0002-9149(05)80034-7","article-title":"Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage","volume":"76","author":"Smit","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/ENDO:22:2:151","article-title":"Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients","volume":"22","author":"Sonmez","year":"2003","journal-title":"Endocrine"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2265.2006.02510.x","article-title":"The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia","volume":"64","author":"Sonmez","year":"2006","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005344-200003000-00003","article-title":"Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels","volume":"35","author":"Spieker","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0187|cit187","first-page":"IV28","article-title":"Combination drug therapy for hyperlipidemia \u00a0associated included citation for the Sprecher 1994 trial","volume":"17","author":"Jacobson","year":"1994","journal-title":"Clinical Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-120-7-199404010-00002","article-title":"Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients","volume":"120","author":"Sprecher","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0189|cit189","unstructured":"Novartis Pharma Services AG A 12-week multicentre, double blind, double dummy, randomized, parallel group, active controlled study to evaluate the efficacy and tolerability of fluvastatin extended release (Lescol XL\u00c2\u00ae 80 mg) alone or in combination with ezetimibe10 mg as compared to ezetimibe monotherapy, in dyslipidemic patients with previous history of muscular complaints with other statins EU Clinical Trials Register 2005"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0191|cit191","unstructured":"Stein EA Ruben C Gimpelewicz R Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins Patent US 2009\/0275551 A1"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0192|cit192","unstructured":"EudraCt Fluvastatin 80 mg ret. vs combination with ezetimib 10 mg EU Clinical Trials Register Number 2004-002535-12 2004"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2362.2009.02249.x","article-title":"Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events","volume":"40","author":"Stojakovic","year":"2010","journal-title":"European Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0194|cit194","first-page":"33","article-title":"Fluvastatin treatment of hyperlipoproteinemia in patients with non-insulin-dependent diabetes mellitus","volume":"38","author":"Susekov","year":"1998","journal-title":"Kardiologiya"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/107424840400900204","article-title":"Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity","volume":"9","author":"Tambaki","year":"2004","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0002-9149(99)00471-3","article-title":"Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus","volume":"84","author":"Tan","year":"1999","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"110A","DOI":"10.1016\/S0002-9149(05)80030-X","article-title":"Effects of fluvastatin on human biliary lipids","volume":"76","author":"Tazuma","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MCA.0b013e32830d27d2","article-title":"Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure","volume":"19","author":"Tekin","year":"2008","journal-title":"Coronary Artery Disease"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"136A","DOI":"10.1016\/S0002-9149(05)80036-0","article-title":"Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia","volume":"76","author":"Tomlinson","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000082166","article-title":"Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients","volume":"22","author":"Tsirpanlis","year":"2004","journal-title":"Blood Purification"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1185\/030079907X187847","article-title":"Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study)","volume":"23","author":"Ilerigelen","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0202|cit202","first-page":"8","article-title":"[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia]","volume":"70","author":"Tvorogova","year":"1998","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-8-1","article-title":"Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report","volume":"8","author":"Valdivielso","year":"2009","journal-title":"Cardiovascular Diabetology"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00044011-200121100-00001","article-title":"Treatment of dyslipidemia with fluvastatin in patients with type 2 diabetes mellitus: effects on lipids, mental state and fibrinolysis","volume":"21","author":"Visseren","year":"2001","journal-title":"Clinical Drug Investigation"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0205|cit205","first-page":"1284","article-title":"Observation on effects of short term cholesterol-lowering therapy with low-dosage Fluvastatin on NO and endothelial function in patients with hypercholesterolemia. [Chinese]","volume":"20","author":"Wang","year":"2004","journal-title":"Chinese Pharmacological Bulletin"},{"issue":"25","key":"10.1002\/14651858.CD012282.pub2-BIB0206|cit206","first-page":"11","article-title":"[The Effect of Fluvastatin and Xuezh ik ang on Serum Lipid in Patients with Cerebral Infarction and Hyper Lipidemia]","volume":"27","author":"Wang","year":"2008","journal-title":"China Foreign Medical Treatment [Zhong Wai Yi Liao]"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0002-9343(01)00679-9","article-title":"Effects of 1-year treatment with fluvastatin or pravastatin on bone","volume":"110","author":"Watanabe","year":"2001","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00045391-199809000-00002","article-title":"Fluvastatin titrate-to-goal clinical practice study","volume":"5","author":"Weiss","year":"1998","journal-title":"American Journal of Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1210\/jc.2003-031494","article-title":"Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: A placebo-controlled trial in patients with type 2 diabetes","volume":"89","author":"Winkler","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1210\/jc.2002-020370","article-title":"Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action","volume":"87","author":"Winkler","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00007256-199927050-00004","article-title":"Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism","volume":"27","author":"Wittke","year":"1999","journal-title":"Sports Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012282.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1726-4901(09)70175-3","article-title":"Efficacy and safety of slow-release fluvastatin 80 mg daily in Chinese patients with hypercholesterolemia","volume":"68","author":"Wu","year":"2005","journal-title":"Journal of the Chinese Medical Association : JCMA"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"662","DOI":"10.5551\/jat.1438","article-title":"Evaluation of plaque stabilization by fluvastatin with carotid intima- medial elasticity measured by a transcutaneous ultrasonic-based tissue characterization system","volume":"16","author":"Yamagishi","year":"2009","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0214|cit214","first-page":"651","article-title":"[Clinical safety and tolerability of long-term treatment with fluvastatin (XU62-320) in hypercholesterolemia: ophthalmological effect]","volume":"11","author":"Yamamoto","year":"1995","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1081\/JDI-120039826","article-title":"Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease","volume":"26","author":"Yasuda","year":"2004","journal-title":"Renal Failure"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"12D","DOI":"10.1016\/0002-9149(94)90627-0","article-title":"Clinical implications of the biopharmaceutical properties of fluvastatin","volume":"73","author":"Deslypere","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"12 SUPPL.","key":"10.1002\/14651858.CD012282.pub2-BIB0217|cit217","first-page":"IV11","article-title":"Clinical reviews of fluvastatin: Short-term and long-term data","volume":"17","author":"Troendle","year":"1994","journal-title":"Clinical Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0218|cit218","first-page":"63","article-title":"Clinical experience with fluvastatin----the first synthetic HMG-CoA reductase inhibitor","volume":"21","author":"Zavoral","year":"1996","journal-title":"P & T Journal"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MCA.0000000000000054","article-title":"Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X","volume":"25","author":"Zhang","year":"2014","journal-title":"Coronary Artery Disease"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0220|cit220","first-page":"241","article-title":"Effect of fluvastatin on dyslipidaemia associated with type 2 diabetes mellitus","volume":"15","author":"Afzal","year":"1999","journal-title":"Specialist"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0041-1345(01)01966-2","article-title":"Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients","volume":"33","author":"Akiyama","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.ki.5000327","article-title":"Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency","volume":"69","author":"Alaupovic","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-0037-1613755","article-title":"Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients","volume":"83","author":"Ambrosi","year":"2000","journal-title":"Thrombosis & Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.atherosclerosis.2004.08.033","article-title":"Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives","volume":"178","author":"Anderssen","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00149-1","article-title":"Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients","volume":"164","author":"Asztalos","year":"2002","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/106002809603001204","article-title":"Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy","volume":"30","author":"Austen","year":"1996","journal-title":"Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0002-9149(00)01076-6","article-title":"Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia","volume":"86","author":"Ballantyne","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s15010-004-3136-7","article-title":"Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir","volume":"32","author":"Benesic","year":"2004","journal-title":"Infection"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0002-9149(01)01486-2","article-title":"Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate","volume":"87","author":"Blann","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1034\/j.1399-0004.2001.590604.x","article-title":"LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy","volume":"59","author":"Brorholt-Petersen","year":"2001","journal-title":"Clinical Genetics"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"129A","DOI":"10.1016\/S0002-9149(05)80035-9","article-title":"Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia","volume":"76","author":"Broyles","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0232|cit232","first-page":"5","article-title":"[Effect of fluvastatin on plasma endothelin and platelet aggregation in elderly hypertensive patients with hypercholeoterolemia]","volume":"3","author":"Chen","year":"2001","journal-title":"Geriatrics and Health Care"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2125.1996.03415.x","article-title":"A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects","volume":"41","author":"Eagles","year":"1996","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00005344-200005000-00009","article-title":"Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease","volume":"35","author":"Eichstadt","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"122A","DOI":"10.1016\/S0002-9149(05)80033-5","article-title":"Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease","volume":"76","author":"Eichstadt","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0236|cit236","first-page":"157","article-title":"Does fluvastatin improve arterial functions in dyslipidemic renal transplant recipients?","volume":"25","author":"Ersoy","year":"2014","journal-title":"Biomedical Research (India)"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0237|cit237","unstructured":"EudraCt Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome - niaspan in combination with fluvasttin compared to fluvastatin monotherapy for metabolic syndrome EudraCT Number 2005-003812-31 2006"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0238|cit238","first-page":"2579","article-title":"The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients","volume":"27","author":"Ghods","year":"1995","journal-title":"Transplantation Proceedings"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/00007890-199612150-00005","article-title":"Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine","volume":"62","author":"Goldberg","year":"1996","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"107A","DOI":"10.1016\/S0002-9149(05)80029-3","article-title":"A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine","volume":"76","author":"Goldberg","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0041-1345(99)00362-0","article-title":"Fluvastatin in the treatment of hypercholesterolemia in renal transplantation","volume":"31","author":"Gomez","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00001721-199904000-00004","article-title":"Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin","volume":"10","author":"Gottsater","year":"1999","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.99.4.475","article-title":"Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin","volume":"99","author":"Guethlin","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2006.11.152","article-title":"The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure","volume":"123","author":"Gurgun","year":"2008","journal-title":"International Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0246|cit245","first-page":"375","article-title":"Fluvastatin vs. lovastatin in primary hypercholesterolemia \u00a0associated excluded citation for the Haasis 1996 trial","volume":"27","author":"Haasis","year":"1995","journal-title":"Herz Kreislauf"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0245|cit246","first-page":"145","article-title":"A pharmacoeconomic evaluation of fluvastatin and lovastatin in primary hypercholesterolaemia","volume":"10","author":"Haasis","year":"1996","journal-title":"British Journal of Medical Economics"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00191909","article-title":"Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine","volume":"46","author":"Hagen","year":"1994","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/ATVBAHA.106.128793","article-title":"Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase","volume":"27","author":"Haramaki","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0249|cit249","first-page":"165","article-title":"Fluvastatin versus pravastatin in treating hyperlipidemia","volume":"20","author":"He","year":"2001","journal-title":"China Pharmacist"},{"issue":"10","key":"10.1002\/14651858.CD012282.pub2-BIB0250|cit250","first-page":"608","article-title":"[Effect of Xue Zhi Kang on blood fat and C-reactive protein of aged people]","volume":"17","author":"He","year":"2007","journal-title":"Zhejiang Journal of Integrated Traditional Chinese and Western Medicine [zhe Jiang Zhong Xi Yi Jie He za Zhi]"},{"issue":"May-Jun","key":"10.1002\/14651858.CD012282.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"241","DOI":"10.18553\/jmcp.2000.6.3.241","article-title":"Comparative cost effectiveness of fluvastatin and lovastatin in patients with hypercholesterolemia","volume":"6","author":"Hilleman","year":"2000","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstrom","year":"2004","journal-title":"Kidney international"},{"issue":"9374","key":"10.1002\/14651858.CD012282.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"102A","DOI":"10.1016\/S0002-9149(05)80028-1","article-title":"Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine","volume":"76","author":"Holdaas","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1253\/circj.72.722","article-title":"Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study","volume":"72","author":"Hongo","year":"2008","journal-title":"Circulation Journal : official journal of the Japanese Circulation Society"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/107424849600100105","article-title":"A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin","volume":"1","author":"Illingworth","year":"1996","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2169\/internalmedicine.50.4059","article-title":"Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET)","volume":"50","author":"Inoue","year":"2011","journal-title":"Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"47A","DOI":"10.1016\/S0002-9149(05)80016-5","article-title":"Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia","volume":"76","author":"Koizumi","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0259|cit259","first-page":"55","article-title":"[The effect of fluvastatin (Lescol) treatment on the clinical status and function of the liver in patients with ischemic heart disease]","volume":"69","author":"Kuril'skaia","year":"1997","journal-title":"Terapevticheskii Arkhiv"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/039139889702000105","article-title":"Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation","volume":"20","author":"Lal","year":"1997","journal-title":"International Journal of Artificial Organs"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007890-199510150-00006","article-title":"Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia","volume":"60","author":"Li","year":"1995","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02551424","article-title":"Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants","volume":"29","author":"Locsey","year":"1997","journal-title":"International Urology & Nephrology"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD012282.pub2-BIB0263|cit263","first-page":"IV16","article-title":"Fluvastatin titrate-to-goal clinical practice study: Interim results","volume":"17","author":"Marcus","year":"1994","journal-title":"Clinical Cardiology"},{"issue":"3-4","key":"10.1002\/14651858.CD012282.pub2-BIB0264|cit264","first-page":"11","article-title":"A clinical trial of fluvastatin in hypertensive patients","volume":"33","author":"Mattu Siddiqui","year":"2000","journal-title":"Pakistan Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000013504","article-title":"Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome","volume":"19","author":"Matzkies","year":"1999","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0266|cit266","unstructured":"Merck Sharp Dohme Corp Observational study of approaches to lipid-lowering therapy in Russian patients with coronary heart disease <<Treat to Goal>> (Study P05464) ClinicalTrials.gov Identifier: NCT00730132 2015"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1507\/endocrj.52.259","article-title":"Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients","volume":"52","author":"Miwa","year":"2005","journal-title":"Endocrine Journal"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD012282.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0002-8703(99)70261-9","article-title":"Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders","volume":"138","author":"Murdock","year":"1999","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0269|cit269","unstructured":"NOVARTIS An open-label prospective multicentre study to determine the efficacy, tolerability and effect on patientcompliance of fluvastatin 80 mg treatment in patients with primary hypercholesterolemia Study Number CXUO320BTR02 2003"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0270|cit270","unstructured":"NOVARTIS A double-blind, randomised, placebo -controlled, 4-armed, 3-period cross-over study to investigatethe effect on endothelial function of the combination therapy fluvastatin 80 mg SR and valsartan 160 mg,monotherapy fluvastatin 80 mg SR, and monotherapy valsartan 160 mg in comparison to placebo inpatients with type 2 diabetes mellitus Study Number CXUO320DE21 2004"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0271|cit271","unstructured":"NOVARTIS A multicenter, randomized, double-blind, 5-week cross-over study to investigate pleiotropic effectsof fluvastatin 80 mg ER and fluvastatin 40 mg bid IR in comparison to placebo in patientswith Metabolic Syndrome Study Number CXUO230BDE30 2006"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0272|cit272","unstructured":"NOVARTIS Efficacy and safety of fluvastatin sodium extended release tablets 80 mg once daily in Chinese patients with primary hypercholesterolemia or mixed dyslipidemia ClinicalTrials.gov Identifier: NCT01551173 2012"},{"issue":"2-3","key":"10.1002\/14651858.CD012282.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijcard.2003.04.009","article-title":"Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study","volume":"94","author":"O'Rourke","year":"2004","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0274|cit274","unstructured":"Novartis Fluvastatin in patients with Acute Coronary Syndrome (FACS study) Study Number: CXUO320BCZ01 2006"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0275|cit275","unstructured":"Novartis Fluvastatin\u00a0in the therapy of Acute Coronary Syndrome ClinicalTrials.gov 2010"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0276|cit276","first-page":"61","article-title":"Fluvastatin in the First-line therapy of Acute Coronary Syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)","volume":"11","author":"Ostadal","year":"2010","journal-title":"Trials [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00044011-199918030-00005","article-title":"Comparison of the lipid-lowering effects of fluvastatin, lovastatin and simvastatin in patients with hyperlipoproteinaemia. An internally controlled clinical study","volume":"18","author":"Paragh","year":"1999","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012282.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2165\/00003495-199400472-00012","article-title":"Efficacy and safety of fluvastatin in women with primary hypercholesterolemia","volume":"47","author":"Peters","year":"1994","journal-title":"Drugs"},{"issue":"1-2","key":"10.1002\/14651858.CD012282.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0041-1345(96)00646-X","article-title":"Treatment of metabolic disorders with fluvastatin after renal transplantation","volume":"29","author":"Podder","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/j.1875-9114.1998.tb03905.x","article-title":"A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia","volume":"18","author":"Rindone","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.TP.0000443225.66960.7e","article-title":"More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients","volume":"97","author":"Robertsen","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0282|cit282","first-page":"183","article-title":"Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide","volume":"48","author":"Romano","year":"2000","journal-title":"Journal of Investigative Medicine : the official publication of the American Federation for Clinical Research"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/ajkd.2002.29883","article-title":"Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency","volume":"39","author":"Samuelsson","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000177324","article-title":"Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol","volume":"88","author":"Sasaki","year":"1997","journal-title":"Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2003.09.008","article-title":"Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects","volume":"93","author":"Schaefer","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/000331979804901006","article-title":"Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin","volume":"49","author":"Schobel","year":"1998","journal-title":"Angiology"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00007890-199811150-00011","article-title":"Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test","volume":"66","author":"Schrama","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"88","DOI":"10.13181\/mji.v17i2.309","article-title":"Safety and tolerability of fluvastatin XL in the treatment of hyper-cholesterolemia: A postmarketing surveillance conducted in Indonesia","volume":"17","author":"Setiawati","year":"2008","journal-title":"Medical Journal of Indonesia"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/liv.12316","article-title":"Omega-3 fatty acids and\/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial","volume":"34","author":"Sheridan","year":"2014","journal-title":"Liver International"},{"issue":"9","key":"10.1002\/14651858.CD012282.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"678","DOI":"10.7326\/0003-4819-122-9-199505010-00006","article-title":"Effects of alcohol and fluvastatin on lipid metabolism and hepatic function","volume":"122","author":"Smit","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012282.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"33A","DOI":"10.1016\/S0002-9149(05)80013-X","article-title":"Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients","volume":"76","author":"Teramoto","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1023\/A:1015052312866","article-title":"The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study","volume":"32","author":"Turk","year":"2001","journal-title":"International Urology & Nephrology"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0293|cit293","unstructured":"Novartis EXECUTIVE SUMMARY FOR PEDIATRIC SUPPLEMENT FDA 2006"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0294|cit294","unstructured":"Novartis Efficacy and safety of fluvastatin in children with heterozygous familial hypercholesterolemia ClinicalTrials.gov 2005"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0295|cit295","unstructured":"Novartis Open-label, phase III, dose-titration, multicenter study to assess the efficacy and safety offluvastatin sodium capsules and fluvastatin sodium extended -release (XL) tablets (20, 40 and 80 mg)given orally at bedtime for 114 weeks in pediatric patients with heterozygous familial hypercholesterolemia Study Number: CXUO320B2301 2006"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/08035250600702602","article-title":"Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia","volume":"95","author":"Graaf","year":"2006","journal-title":"Acta Paediatrica"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.HYP.0000221223.23028.f1","article-title":"Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin \u00a0","volume":"47","author":"Linde","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0953-6205(01)00172-8","article-title":"Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein","volume":"12","author":"Haelst","year":"2001","journal-title":"European Journal of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/0003319708316005","article-title":"Fluvastatin treatment and withdrawal: effects on endothelial function","volume":"59","author":"Westphal","year":"2008","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MCA.0b013e32831a8811","article-title":"Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction","volume":"20","author":"Westphal","year":"2009","journal-title":"Coronary Artery Disease"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0301|cit301","first-page":"419","article-title":"Czech and Slovak fluvastatin study in patients with severe hyperlipidemia. [Czech]","volume":"43","author":"Widimsky","year":"1997","journal-title":"Vnitrni Lekarstvi"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0302|cit302","first-page":"210","article-title":"[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate]","volume":"45","author":"Widimsky","year":"1999","journal-title":"Vnitrni Lekarstvi"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0303|cit303","first-page":"2936","article-title":"Clinical efficacy of different doses of fluvastatin on patients with coronary heart disease combined with hyperlipidemia","volume":"14","author":"Wu","year":"2014","journal-title":"Progress in Modern Biomedicine"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0304|cit304","first-page":"260","article-title":"Statin therapy may prevent Restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level","volume":"98","author":"Yamawaki","year":"2007","journal-title":"Fukuoka Acta Medica"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0305|cit305","first-page":"264","article-title":"Effects of fluvastatin on platelet activation and insulin resistance in patients with primary hypercholesterolemia","volume":"28","author":"Yang","year":"2000","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"issue":"2-3","key":"10.1002\/14651858.CD012282.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0021-9150(91)90017-W","article-title":"Effects of fluvastatin XU 62-320 an HMG-Coenzyme a reductase inhibitor on the distribution and composition of low density lipoprotein subspecies in humans","volume":"87","author":"Yuan","year":"1991","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5551\/jat.12.41","article-title":"A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia","volume":"12","author":"Zhang","year":"2005","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0308|cit308","first-page":"455","article-title":"[Efficacy and safety of fluvastatin extended-release tablets in Chinese patients with hyperlipidemia: a multi-center, randomized, double-blind, double dummy, active-controlled, parallel-group study]","volume":"53","author":"Zhao","year":"2014","journal-title":"Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0309|cit309","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010254.pub2","article-title":"Rosuvastatin for lowering lipids","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012282.pub2-BIB0310|cit310","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008226.pub3","article-title":"Atorvastatin for lowering lipids","author":"Adams","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0311|cit311","unstructured":"Bandolier Cholesterol lowering with statins Bandolier 2004 121 2"},{"issue":"9493","key":"10.1002\/14651858.CD012282.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Cholesterol Treatment Trialists' (CTT)","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2296-4-18","article-title":"Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials","volume":"4","author":"Edwards","year":"2003","journal-title":"BMC Family Practice"},{"issue":"2A","key":"10.1002\/14651858.CD012282.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0002-9343(98)00038-2","article-title":"Cholesterol lowering in the management of coronary artery disease: the implications of recent trials","volume":"104","author":"Eisenberg","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012282.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0316|cit316","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003823.pub2","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Heran","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0318|cit318","unstructured":"Higgins JPT Green S (editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"11","key":"10.1002\/14651858.CD012282.pub2-BIB0319|cit319","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009462.pub2","article-title":"Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia","author":"Izquierdo-Palomares","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012282.pub2-BIB0320|cit320","first-page":"352","article-title":"Focus on atorvastatin: An HMG-CoA reductase inhibitor for lowering both elevated LDL cholesterol and triglycerides in hypercholesterolemic patients","volume":"32","author":"Kellick","year":"1997","journal-title":"Formulary"},{"issue":"7404","key":"10.1002\/14651858.CD012282.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"5","key":"10.1002\/14651858.CD012282.pub2-BIB0323|cit323","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003824.pub2","article-title":"Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension","author":"Musini","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"23","key":"10.1002\/14651858.CD012282.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)","volume":"269","author":"NCEP Expert","year":"1993","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0325|cit325","unstructured":"The Nordice Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"12","key":"10.1002\/14651858.CD012282.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"990","DOI":"10.7326\/0003-4819-125-12-199612150-00011","article-title":"Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment","volume":"125","author":"Schectman","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0327|cit327","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH (editors) Chapter 11: Presenting results and \u2019Summary of findings\u2019 tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0328|cit328","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0329|cit329","unstructured":"Smith MEB Lee NJ Haney E Carson S Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin. Final Report Update 5, 2009 www.ncbi.nlm.nih.gov\/books\/NBK47273\/pdf\/TOC.pdf"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0330|cit330","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD012282.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharmacogenomics Journal"},{"key":"10.1002\/14651858.CD012282.pub2-BIB0332|cit332","unstructured":"Tsang MB Adams SP Jauca C Wright JM In some systematic reviews placebos may not be necessary: an example from a statin dose-response study 10th Cochrane Colloquium Stavanger Poster 29"},{"issue":"14","key":"10.1002\/14651858.CD012282.pub2-BIB0333|cit333","first-page":"1-160, iii-iv","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"7","key":"10.1002\/14651858.CD012282.pub2-BIB0334|cit334","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012282","article-title":"Fluvastatin for lowering lipids","author":"Adams","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012282.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T19:26:37Z","timestamp":1719861997000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012282.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":334,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012282.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]}}}